Browse
Submit Data
Databases
API
Help

Dataset Information

79 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

ABSTRACT: This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

DISEASE(S): Colorectal Carcinoma,Squamous Cell Carcinoma Of Head And Neck,Carcinoma,Squamous Cell Carcinoma Of The Head And Neck,Non-small Cell Lung Cancer,Colorectal Neoplasms,Carcinoma, Renal Cell,Renal Cell Carcinoma

PROVIDER: 12611 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Project description:This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SM04755 administered orally. Upon determination of the maximum tolerated dose (MTD), expansion cohorts may be enrolled.

| 2170682 | ecrin-mdr-crc

BMS_IM125001_WB_study

Project description:The goal of this study is to define the molecular signatures of prednisolone and BMS-791826 in normal healthy volunteers. IM125001 (NCT03198013) is a phase I, placebo-controlled, double-blind, ascending single and multiple oral dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of bms-791826 and to assess its marker specific pharmacodynamics in relation to prednisolone in healthy males, sponsored by Bristol-Myers Squibb.

2018-02-06 | GSE110161 | GEO

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

Project description:This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in patients with advanced solid tumours.

| 2371502 | ecrin-mdr-crc

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 4/6

Project description:During discovery and development of protein-based drugs, extensive animal testing is required for preclinical analysis of pharmacokinetics, tissue biodistribution, toxicity, etc. Generally, several animals are required for testing a single drug. We show that the use of genetically encoded peptide barcodes, called flycodes, allows for the simultaneous preclinical assessment of dozens of antibodies from single cassette-dosed mice. Datasets: 1. comparison of flycodes vs. unique endogenous tryptic peptides for antibody identification 2. antibody PK, cassette dose A (high dose) 3. antibody PK, cassette dose B (low dose) 4. antibody tumor/organ biodistribution 5. Dar-SB thermostability 6. Dar-SB PK

2025-02-26 | PXD036662 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 1/6

2025-02-26 | PXD036658 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 2/6

2025-02-26 | PXD036734 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 5/6

2025-02-26 | PXD036666 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 3/6

2025-02-26 | PXD036661 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 6/6

2025-02-26 | PXD036668 | Pride

Mass Spectrometry Methods and Mathematical PK/PD Model for Decision Tree-Guided Covalent Drug Development

Project description:Covalent drug discovery efforts are growing rapidly but have major unaddressed limitations. These include high false positive rates during hit-to-lead identification; the inherent uncoupling of covalent drug concentration and effect [i.e., uncoupling of pharmacokinetics (PK) and pharmacodynamics (PD)]; and a lack of bioanalytical and modeling methods for determining PK and PD parameters. We present a covalent drug discovery workflow that addresses these limitations. Our bioanalytical methods are based upon a mass spectrometry (MS) assay that can measure the percentage of drug-target protein conjugation (% target engagement) in biological matrices. Further we develop an intact protein PK/PD model (iPK/PD) that outputs PK parameters (absorption and distribution) as well as PD parameters (mechanism of action, protein metabolic half-lives, dose, regimen, effect) based on time-dependent target engagement data. Notably, the iPK/PD model is applicable to any measurement (e.g., bottom-up MS and other drug binding studies) that yields % of target engaged. A Decision Tree is presented to guide researchers through the covalent drug development process. Our bioanalytical methods and the Decision Tree are applied to two approved drugs (ibrutinib and sotorasib); the most common plasma off-target, human serum albumin; three protein targets (KRAS, BTK, SOD1), and to a promising SOD1-targeting ALS drug candidates.

2025-01-23 | PXD046903 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data